Symptoms of gastro-esophageal reflux disease (GERD)have a substantial impact on patients' everyday lives.
Dr Roger Jones and colleagues from the UK, USA and Sweden developed and tested a short questionnaire to aid patient-doctor communication.
The GERD Impact Scale was developed from a systematic literature review, focus groups of patients and primary care physicians, and patient cognitive interviews.
|77% of doctors found the scale useful.|
| Alimentary Pharmacology & Therapeutics |
A psychometric validation study was conducted based on two consultations in new (n= 100) or chronic (n = 105) patients with GERD.
The GERD Impact Scale demonstrated internal consistency (Cronbach's alpha ranged from 0.68 to 0.82), reproducibility (intraclass correlation coefficient in stable patients ranged from 0.61 to 0.72) and construct validity (Spearman correlations with Quality of Life in Reflux and Dyspepsia instrument and Reflux Disease Questionnaire: 0.5-0.8 in both patient groups).
Effect sizes in new and chronic GERD patients ranged from 0.9 to 1.5 and 0.32 to 0.42, respectively.
Doctors reported altering their treatment decision based on information provided by the GERD Impact Scale in 35% of patients, and 77% of doctors found it to be useful.
Dr Roger Jones found that the GERD Impact Scale demonstrated good psychometric properties in newly diagnosed patients with GERD and those already receiving treatment.
He concluded that, "This simple communication tool is a useful aid for managing primary care patients with GERD".